MEDIAN OVERALL SURVIVAL DATA:
ABRAXANE VS PACLITAXEL INJECTION21

ITT population: no statistically significant difference between ABRAXANE vs paclitaxel injection
ABRAXANE® for metastatic breast cancer (MBC) median overall survival analysis in ITT population from phase III clinical trial - Kaplan-Meier curve
  • b Median overall survival was measured in weeks and converted to months (assuming 4.348125 weeks in 1 Gregorian month).
Post-hoc analysisa in patients who received at least one prior chemotherapy for metastatic disease
ABRAXANE® for metastatic breast cancer (MBC) median overall survival post-hoc exploratory analysis from phase III clinical trial - Kaplan-Meier curve
aAnalysis Limitations: A post-hoc exploratory analysis should not be interpreted to determine a treatment difference between arms in this selected subgroup because of potential selection bias, insufficient sample size, and a higher probability of making a false positive finding.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL